

# SOHO UK – Chairs and Speakers



**Charles Craddock CBE**  
**Co-Chair for Organising Committee**

Professor Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematology at University Hospitals Birmingham. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He is a past President of the British Society of Haematology. Professor Craddock pioneered the development of both the UK Haemato-oncology Trials Acceleration Programme and stem cell transplant trials network, IMPACT. In 2021 he founded Accelerating Clinical Trials Ltd, an innovative haemato-oncology trials delivery vehicle. He has published more than 275 papers in peer reviewed journals. Professor Craddock was awarded the CBE for services to medicine in the 2016 New Year's Honours list and elected a Fellow of the Academy of Medical Sciences in 2020.



**Anthony Goldstone CBE**  
**Co-Chair for Organising Committee**

Tony Goldstone's main contribution has been as a Consultant Haematologist in Adult Malignancy from 1976-2011 at UCH/UCL. He began the transplant programme, helped lead the new build as Medical Director & started to build what has now become the biggest adult Haem malignancy unit in Europe. He has long had an interest in Medical leadership, hospital management & mentoring. He has been President of the BSH, Chair & initiator of the EBMT Lymphoma Group, Chair of the RNOH NHS Trust, Chair of Cancer at HCA & was a past President of SOHO. He relaxes in his retirement as Medical Director of 18 Week Support, an Insourcing company shortening NHS waiting lists.



**David Cairns**

Professor David Cairns is Professor of Clinical Trials Research and Deputy Director of the Leeds Cancer Research UK Clinical Trials Unit at the Leeds Institute of Clinical Trials Research (LICTR). His work focuses on the design, conduct, and analysis of large, confirmatory cancer clinical trials, particularly in haematological malignancies such as multiple myeloma and chronic lymphocytic leukaemia, as well as selected solid tumours. His research spans efficient trial design, biomarker driven treatment pathways, and the integration of translational science to inform and improve future studies. He also has developing interests in the use of routinely collected healthcare system data to enhance trial efficiency, optimise trial delivery, and improve patient outcomes.



**Catherine Cargo**

Dr Catherine Cargo is a Consultant Haematologist and Clinical Lead in the Haematological Malignancy Diagnostic Service (HMDS) in Leeds, UK. She graduated from Queens University, Belfast and completed post graduate training in the Belfast City Hospital completing an MSc in Haematopathology through the University of York. Her clinical interest is in the diagnosis and management of chronic myeloid malignancies, in particular MDS, and she sits on the UK MDS research network group and is vice chair of the BSH MDS Special Interest Group. She has a strong genomic background having completed a PhD exploring the use of molecular diagnostic technologies in low risk MDS and CMML and has a specific research interest in CCUS and inflammatory MDS. She is also the Clinical Lead for Haemato-Oncology genomics within the North East and Yorkshire region contributing to the genomics testing strategy both regionally and nationally. Internationally she sits on the executive committee for the EUMDS registry and the EHA Specialized Working Group on MDS and is a member of the IWG for prognosis in MDS (IWG-PM).



**Sridhar Chaganti**  
**ALL and Cell Therapy Lead for Organising Committee**

Dr Chaganti is a Consultant Haemato-Oncologist at the University Hospital Birmingham (UHB), UK with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the clinical lead for lymphoid diseases and his research interests include aggressive lymphomas including Epstein Barr Virus-associated lymphomas and post-transplant lymphoproliferative disorders. He is a member of the UK Lymphoma Research Group and Chair of the High Grade Lymphoma subgroup. He is an author/ co-author on a number of scientific publications and BSH guidelines for lymphoma. He has served as a clinical expert for NICE technology appraisals and NICE scientific advice committees for lymphoma and CAR T-cell therapies. He is a chief investigator / principal investigator for several clinical trials in lymphoma, ALL and CAR T-cell therapies.



**Tom Coats**

Tom is a Haematology Consultant at the Royal Devon University Hospital. He is a member of the UK AML Steering Committee and Genomic Lab Hub Haem-onc subspeciality lead for the South West. Tom is a passionate advocate for using technology and consensus-based recommendations to improve decision-making and outcomes in AML.



**Matthew Collin**

Matthew Collin is Professor of Haematology at Newcastle University and Newcastle upon Tyne Hospitals NHS foundation Trust. He received a PhD from Oxford University in 1992, supervised by Siemon Gordon and graduated with an MD in 1995. After a year at the South Island Bone Marrow Transplant Unit in Christchurch with Derek Hart, he moved to Newcastle in complete training in haematology. He received a Leukaemia Research Fund UK Bennett Senior Fellow in Experimental Haematology in 2006 and spent one year in the lab of Miriam Merad. Back in Newcastle he set up the Human DC Lab (<http://www.hudendritic.org>) where he continues as Co-PI with Venetia Bigley. His work has focussed on analysing human DC in vivo, from defining the subsets of interstitial DC and mapping their correspondence with murine DC, to identifying genes controlling human DC development, and the contribution of DC deficiency to primary immunodeficiency. He has also made contributions to the field of histiocytosis and is currently interested in the influence of somatic mutation on immunity.



**Graham Collins**  
**Lymphoma Lead for Organising Committee**

Graham Collins is Associate Professor of Haematology at the University of Oxford and lymphoma lead clinician at Oxford University Hospitals NHS Foundation Trust. His main academic interests are in Hodgkin lymphoma and high-grade non-Hodgkin lymphoma, both B-cell and T-cell. He is chief investigator for a number of investigator-initiated studies and pharmaceutical studies in these disease areas and he is past chair of the UK Hodgkin and T-cell lymphoma study groups. He is currently chair of the UK National CAR T-cell Clinical Panel. He was part of the NICE guidelines development group for non-Hodgkin lymphoma and has co-authored national guidelines for Hodgkin lymphoma and T-cell lymphoma.



**Gordon Cook**  
**Myeloma Lead for Organising Committee**

Gordon Cook is the Professor of Haematology at University of Leeds, Visting Professor in Health Sciences at the University of York, Co-Director of the Leeds Cancer Research Centre and Clinical Director (Haematology), CRUK Clinical Trials Research Unit, University of Leeds and Dean of the College of Myeloma (UK). He is a NIHR Senior Investigator. He was the founder & first Chair of the UK Myeloma Research Alliance and the past-chair of the UK Myeloma Society. He established the College of Myeloma (UK) which elected its first fellows in 2019. Professor Cook is the NHS England Advanced Cellular Therapies Lead for myeloma. He was appointed as the chair of the NCRI Haemato-oncologist Clinical Studies Group in 2022, and is the co-creator of the UK Blood Cancer Research Network. He has developed and delivered an extensive national clinical research portfolio and is the Chief investigator of 6 multi-centre phase III interventional studies, the chief investigator of 5 investigator-initiated early phase studies and the UK chief investigator on 6 industry-lead phase III/IIIb studies.



**Mhairi Copland**  
**CML and DIDACT Educational Lead for Organising Committee**

Professor of Translational Haematology and Honorary Consultant  
Director of the Paul O’Gorman Leukaemia Research Centre

Professor Mhairi Copland currently splits her time between the Paul O’Gorman Leukaemia Research Centre, where she is Director, and the Beatson West of Scotland Cancer Centre, Glasgow. She has clinical and research interests in chronic myeloid leukaemia and acute leukaemias. She is deputy chair of the UK Blood Cancer Research Network. Specific areas of research interest are clinical trials, leukaemia stem cells, novel, stem-cell directed therapies, treatment resistance and studies of the leukaemic microenvironment. She leads the ACT Trials Acceleration Programme at the Beatson.




**Kate Cwynarski**  
**Lymphoma Lead for Organising Committee**

Professor Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma at University College London Hospital, UK, and Honorary Associate Professor at UCL. She received her MRC-funded PhD in immunology at Imperial College, London, UK. Her sub-specialist interests include central nervous system (CNS) lymphoma, T-cell lymphomas, HIV-related, PTLD and high-grade B-cell lymphomas. She is involved in CAR-T cell trials for refractory DLBCL and T-cell lymphomas. She leads the UK T Cell Lymphoma Group and previously lead the UK CNSL Group and British Society for Haematology (BSH) Lymphoma Specialist Interest Group. She is involved in many clinical trials and has lead and co-authored BSH, EHA and BHIVA guidelines for the management of SCNSL, PCNSL, CNS prophylaxis, T cell lymphoma and primary mediastinal B cell lymphoma. She has co-authored > 150 journal articles.



**Andrew Davies**

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types. Prof Davies specialises in the treatment of malignant lymphoma. He has a particular interest in the investigation of novel therapeutics applied to lymphoma. He has extensive experience in early phase trials, including leading several first in man lymphoma studies all the way through to leading late phase studies. He is Chair of the UK Lymphoma Research Network. He is Director of the Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults (TYA) and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.



**Mike Dennis**  
**AML Lead for Organising Committee**

Mike Dennis has been a Consultant Haematologist at The Christie in since 2004. His clinical practice involves the management of patients with all myeloid disease which require chemotherapy, trials and transplantation. He's fortunate to work as part of yet another great Manchester based team (the other being United). He is an established expert in acute myeloid leukaemia (AML), where his recent roles include Chief investigator (Li1) and Co-chief investigator (AML 19). He regularly performs as clinical expert for NICE technology appraisals in AML. Getting the best possible outcome for AML patients is his primary focus. His research is in clinical trial development for optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance.



**Clair Engelbrecht**

Clair is a registered genetic counsellor with over seven years' experience in clinical genetics, spanning fetal medicine, fertility, cancer genetics, haematology, immunology, and rare diseases. Her research includes health-related quality of life in sickle cell disease and the genetics of inborn errors of immunity. She currently works in the NHS within the myeloid team, providing genetic counselling for patients with or at risk of inherited haematological malignancies, and in the private sector focusing on fertility genetics. Clair is passionate about improving patient care, genetics education, innovation in medicine and supporting individuals and families through complex genetic information.



**Toby Eyre**

Dr Eyre is a Consultant Haematologist specialising in lymphoid malignancies. He has completed an MD Doctorate Thesis in 2017. He is an investigator on several national lymphoid trials and has published over 160 peer-review articles on lymphoma and CLL. He is a core member several lymphoma studies groups. He is a member of the BSH guideline writing groups for various lymphoma subtypes. He is an Associate Editor at the British Journal of Haematology.



**Adele Fielding**  
**ALL Lead for Organising Committee**

Adele Fielding is Professor of Haematology at the University of York. She is the Clinical Director of the Centre for Blood Research and the Head of Experimental Medicine and Biomedicine at Hull York Medical School (HYMS). Her work focuses on acute lymphoblastic leukaemia. She is a clinician-scientist - she is a consultant haematologist at Castle Hill Hospital Hull, she has an active trials portfolio in ALL and she leads a laboratory research group at the University of York Centre for Blood Research focussing on the microenvironment in ALL. She is a past President of the British Society for Haematology (2020-2022). She is the chair of the European Working Group on ALL.



**Chris Fox**  
**Lymphoma Lead for Organising Committee**

Professor Chris Fox (MBChB PhD FRCP FRCPath) is Professor of Haematology at the School of Medicine, University of Nottingham and Consultant Haematologist at Nottingham University Hospitals NHS Trust, UK. His research focuses on the aggressive lymphomas and he currently Chairs the UK's high-grade lymphoma study group. Prof Fox is the Medical Director for the UK TAP (therapy-accelerated programme) blood cancer trials delivery network. He is Chief Investigator and steering committee member for several early and late phase national and international clinical trials. He has co-authored >130 peer-reviewed manuscripts in high-impact journals including NEJM, The Lancet, Lancet Oncology, Lancet Haematology, Journal of Clinical Oncology and Blood.



### **Saar Gill**

Dr Gill obtained his medical degree and PhD in immunology from the University of Melbourne and trained in hematology at St Vincent's Hospital, the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. In 2008 he moved to the United States, first to pursue a post-doctoral fellowship in cellular therapy at Stanford University, and then in 2011 to the University of Pennsylvania where he is now an Associate Professor of Medicine. Dr Gill is also the Scientific Director of Penn's Center for Cell Therapy and Transplantation, and a co-director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. Dr Gill's clinical practice is in leukaemia and bone marrow transplantation. He has led clinical trials of chimeric antigen receptor (CAR) T cells for chronic and acute leukemias. Dr Gill's research laboratory focuses on the interface between adoptive cellular therapy and genetic engineering, with a strong translational focus. Dr Gill has authored over 100 peer-reviewed papers and is listed as an inventor on over 60 patents. He has spun out two biotechnology companies that currently employ over 100 people in Philadelphia. Dr Gill's past trainees hold independent academic appointments at the University of Melbourne, the Israel Institute of Technology, Mayo Clinic, Washington University, and at the University of Pennsylvania School of Medicine.



### **Satyen Gohil**

Dr Satyen Gohil is a Consultant Haematologist at University College Hospital and an Honorary Associate Professor at the University College London Cancer Institute. He specialises in the treatment of CLL, lymphoma and rarer haematological conditions including histiocytic neoplasms and Castleman's Disease. He is the lead haematologist within the multi-speciality haemophagocytic lymphohistiocytosis (HLH) service at UCLH; providing regional and national advice on complex cases, aiming to improve outcomes for this cohort of patients. He undertook a PhD at University College London developing novel immunotherapies for haematological malignancies, one of which is now in clinical trials. He spent 2 years as a postdoctoral fellow at the Dana Farber Cancer Institute and Harvard University analysing mechanisms of response and resistance to immune therapies and better understanding the co-evolution of the immune system with disease.




### **Amanda Goodall**

Amanda Goodall PhD is Professor of Leadership at Bayes Business School (formerly Cass). Her main work analyses the relationship between leadership, management and organisational performance. It shows that leaders who have a deep understanding of the core business ('expert leaders') are associated with better organisational performance, higher employee job satisfaction and fewer quits. Being a good manager alone is not sufficient. Evidence supporting the 'theory of expert leadership' comes from across business, healthcare, universities, Formula 1, basketball, and among professionals. Amanda has also done research into gender differences in pay and negotiation, and she writes on diversity more broadly. Amanda publishes in academic journals, practitioner publications (e.g. HBR) and in the media (e.g. Financial Times). Her recent book "Credible: The Power of Expert Leaders", won the SABEW 2023 Best in Business Book Award for Management and Leadership. She has been a research fellow at Cornell, IZA Institute of Labor Economics in Bonn, University of Zurich and Yale University. She is founder and course director of the Executive Masters in Medical Leadership a programme tailored to the needs of medical doctors. Her research is available at [www.amandagoodall.com](http://www.amandagoodall.com)



**Claire Harrison**  
**MPN Lead for Organising Committee**

Claire Harrison is Deputy Chief Medical Officer at Guy's and St Thomas' NHS Foundation Trust, where she has developed a comprehensive internationally recognised MPN service. Key areas of interest are clinical trials and associated translational research, with global leadership roles in over 20 clinical trials leading to the approval of therapies such as ruxolitinib, fedratinib, momelotinib and pacritinib. She is widely published and is deputy Editor-in Chief of HemaSphere (IF 11.9). Claire has a strong interest in patient advocacy and founded the UK MPN group ([www.mpnvoice.org.uk](http://www.mpnvoice.org.uk)) and an international MPN advocacy network, she is a trustee of Blood Cancer UK.



**Gloria Iacoboni**

Gloria Iacoboni trained in Hematology at La Fe University Hospital in Valencia, Spain. After finishing her Hematology degree, she carried out a 1-year lymphoma fellowship at the Oncology Institute (IOSI) in Lugano, Switzerland (2016-2017). She started working in 2017 at Vall d'Hebron University Hospital (Barcelona, Spain) as a Hematology Consultant focused on clinical trials for lymphoma. She joined the CAR T-cell Program in 2018 with the first clinical trials and, once approved, with the commercially-available CAR-T products. She is currently part of the Advances Therapies Unit and Lymphoma Unit of the Hematology Department, mainly focused on CAR T-cells, bispecific antibodies and other novel immunotherapy strategies for lymphoma patients.



**Wendy Ingram**  
**MDS Lead for Organising Committee**

Dr Wendy Ingram has been a Consultant Haematologist at the University Hospital of Wales, Cardiff, UK since 2010. She specializes in allogeneic stem cell transplantation, myelodysplastic syndromes (MDS), acute myeloid leukaemia and bone marrow failure. Dr Ingram earned her PhD in 'immune biology of AML' from King's College Hospital, London, in 2009. She currently serves as the Deputy Medical Director for the UK IMPACT programme, is an active member of the UK MDS clinical trials subgroup and UK chief investigator and principal investigator for numerous commercial and investigator-led studies in the field of stem cell transplantation.



**Peter Johnson**

Peter Johnson is Professor of Medical Oncology at the University of Southampton, National Clinical Director for Cancer at NHS England and Chair of the UK Office for Life Sciences cancer mission. He was previously Chief Clinician for Cancer Research UK from 2008 to 2017 and set up the UK's first dedicated Centre for Cancer Immunology in Southampton. His research interests are in applied immunology and immunotherapy; lymphoma biology and precision medicine, and clinical trials. He has been the Chief Investigator for trials ranging from first in human novel antibody therapies to international randomised studies. He is currently researching new ways to detect lung cancer at the earliest stage, and leads the NHS Cancer Vaccine Launchpad, aimed at accelerating the next generation of cancer immune treatments.



### **Martin Kaiser**

Professor Martin Kaiser is the Chair of Haematology at the Institute of Cancer Research and a Consultant Haematologist at The Royal Marsden Hospital, London, UK, specialised in the management of multiple myeloma and related plasma cell precursor conditions. A particular focus of his work is high-risk myeloma and personalised patient care. He led the OPTIMUM/MUKnine trial, one of the first trials globally to offer innovative diagnostics and risk-tailored therapy for patients with high-risk myeloma. Prof Kaiser also works on the development of next-generation clinical diagnostics for personalised myeloma patient care, including genomics, advanced MRI imaging technology and bone marrow and blood-based minimal residual disease monitoring, in particular in the context of novel immunotherapies for myeloma. Prof Kaiser has an interest in regulatory policy. He is member of the European Medicine Agency (EMA) EORTC Cancer Medicines Forum, member of the European Haematology Association (EHA) European Affairs and Clinical Research Committees, and an expert advisor to the UK MHRA. He is vice chair and incoming chair of the UK Myeloma Research Alliance (UKMRA), the national trials group, and executive board member of the UK Myeloma Society (UKMS) joining research, policy and advocacy work for patients.



### **Hagop Kantarjian**

Dr Hagop Kantarjian is Chair of the Leukemia Department at MD Anderson Cancer Center in Houston, Texas. He is a fellow in health care policies at the Baker Institute at Rice University. His research focuses on translational-clinical developmental therapeutics in leukemia. Over the past 4 decades, he has made numerous contributions that improved patient prognosis and survival across the leukemia entities, with over 2,400 peer reviewed publications. In addition to his 40+ year career as a leukemia researcher, he has been involved in health care policies, and published extensively on issues related to the Affordable Care Act (ObamaCare), health care as a human right, cancer drug prices, 340B, HPV vaccines, and others.



### **Bruce Keogh KBE**

Sir Bruce has had a distinguished international career as a cardiac surgeon with a longstanding interest in clinical outcomes. He was Professor of Cardiac Surgery at University College London and Director of Surgery at the Heart Hospital, before being appointed Medical Director of the National Health Service in England between 2007-18. During this time as the most senior doctor in the NHS he had particular responsibility for the development and implementation clinical policy, strategy and innovation across the health service in England. He has served on several public and private boards including NHS England and NICE. He is currently Chair of the Birmingham Women's and Children's NHS Foundation Trust. He was knighted for services to medicine in 2003 and was named as one of Britain's 500 most influential people in the Sunday Times in 2014.



### **Anjum Khan**

Dr Khan trained in Haematology in London and was awarded a PhD in Immunology for Haematological Malignancies at the UCL Cancer Institute and Institute of Immunity and Transplantation. He has clinical and research interests in myeloid malignancies, with an overlapping focus on allogeneic stem cell transplantation and immunotherapeutic approaches to treat blood cancers. He has a particular focus on the development of novel lower toxicity treatments accessible to older people, and tailoring care through individualised assessment. As a member of the UK AML Research Network, his research focusses upon applying novel targeted therapies in adverse risk settings and extending the curative potential of cellular therapies.



### **Jean-Jacques Kiladjian**

Jean-Jacques Kiladjian is Professor of Medicine at Université Paris Cité, head of the Clinical Research department of the French National Institute of Health and Medical Research (Inserm), consultant Hematologist and head of the Clinical Investigation Center of the Saint-Louis Hospital, Paris, France. Prof Kiladjian's research has centered on Myeloproliferative neoplasms and Myelodysplastic syndromes. In these disorders, he has been very active in evaluating novel therapeutics and implementing clinical trials. He is published in many peer-reviewed journals including *The New England Journal of Medicine*, *Journal of Clinical Oncology*, *Blood*, *Lancet Haematology*, *HemaSphere*, *Leukemia*, etc., and has authored several book chapters. He is associate Editor of *Leukemia*, *European Journal of Haematology* and *HemaSphere*. He is an active member of many societies including the European Hematology Association (EHA), the American Society of Hematology (ASH), the European LeukemiaNet (ELN), the European School of Hematology (ESH). Prof. Kiladjian was elected President of the French Intergroup of Myeloproliferative disorders (FIM) since 2008. He has provided educational lectures in several French and international meetings over the years, including at the ASH, the EHA, and the American Society of Clinical Oncology (ASCO) annual meetings.



### **Steve Knapper** **AML Lead for Organising Committee**

Steve Knapper combines the role of Professor within the Division of Cancer and Genetics at Cardiff University School of Medicine with clinical work as an Honorary Consultant Haematologist at the University Hospital of Wales (Cardiff & Vale University Health Board) where he currently acts as haematological cancer lead and leads early phase haematological cancer trials and the regional acute leukaemia service. His clinical practice is predominantly in myeloid haematological cancers, particularly acute myeloid leukaemia and the myeloproliferative neoplasms. He is extensively involved in the development of clinical research at a national level as Deputy Chair of the UK AML Research Network and member of the UK Myeloproliferative Neoplasms Clinical Study Group. He is currently chief investigator of the CRUK-funded phase 3 Optimise-FLT3 trial. Other roles include Deputy Medical Director of the UK Trials Acceleration Programme, Joint Lead of the Cardiff CRUK Experimental Cancer Medicine Centre and Chair of the UK ECMC Haematology. His chief lab research interest lies in the development of targeted therapeutic agents in myeloid malignancies; this includes both pre-clinical laboratory studies and clinical research including 'back to bench' laboratory projects running alongside clinical trials.



### **Pramila Krishnamurthy** **Equity and Diversity Lead for Organising Committee**

Dr Pramila Krishnamurthy is a Consultant Haematologist and Honorary Senior Lecturer at King's College Hospital and King's College London respectively. She specialises in acute myeloid leukaemia, myelodysplastic syndromes and stem cell transplantation. She was awarded a John Goldman Fellowship by Leukaemia UK and the Rosetrees Trust in 2021 to study the immunological consequences of donor lymphocyte infusion using samples collected from patients treated on PRO-DLI, the world's first RCT of preventative donor lymphocyte strategies. Additionally, she has interests in quality of life and is leading a study understanding the importance of quality-of-life parameters in relation to treatment outcomes in AML/MDS patients undergoing cytotoxic chemotherapy. She has been Deputy Medical Director of the TAP Clinical Trials Network since 2022 and is committed to increasing access to treatments, including cellular therapies and novel drugs for patients with blood cancer. She is PI on several commercial and academic clinical trials in AML/MDS and transplant within the UK, an active member of the UK IMPACT Transplant Trials Network, secretary of the MDS BSH SIG and member of the UK MDS and AML Research Networks, developing clinical trials for patients with these diseases. She has recently been appointed co-chair of the BSBMTCT Clinical Trials Committee and is a member of the scientific working committee of the BSBMTCT.



### Kim Linton

Kim Linton is a Professor of Medical Oncology at the University of Manchester and an Honorary Consultant at The Christie NHS Foundation Trust, one of Europe's leading cancer centres. She also holds an honorary academic appointment at the University of Liverpool.

A recognised leader in lymphoma clinical research, Prof Linton oversees a portfolio of investigator-led and industry-sponsored clinical trials spanning early-phase, late-phase, and real-world studies. She holds senior roles in several national and international trials, including REFRACT, PETReA, RADAR, EPCORE NHL-1, FOUNDATION UK, BRAMBLE, and UNCOVER PLUS. Her translational research focuses on the late effects of cancer treatment and biomarker development, and she co-leads the Living With and Beyond Cancer Theme within the NIHR Manchester Biomedical Research Centre. Current projects are evaluating lung cancer screening in Hodgkin lymphoma survivors through the SEARCH study, developing proteomic biomarkers for early detection of anthracycline-induced cardiotoxicity, and applying digital pathology for risk stratification in follicular and Hodgkin lymphomas.

Kim chairs the Christie Lymphoma Group and the UK Blood Cancer Biobank Oversight Committee, is a medical advisor for Lymphoma Action and a standing member of the Cancer Research UK Expert Review Group. She contributes to postgraduate education as Course Co-Lead for the MRes Oncology Systemic Therapy Module and lectures on the Oxford Lymphoma Management Course. She supervises PhD and MSc students and provides clinical and educational supervision for oncology trainees.

She is regularly invited to speak at scientific and educational events and contributes to national and international guideline development through roles with NICE, the BSH and EHA. She has authored over 100 peer-reviewed publications. Among her most impactful contributions are studies published in *The Lancet* and *Lancet Haematology* on Epcoritamab-based bispecific antibody therapy for relapsed/refractory B-cell lymphomas, and the MATRix-RICE regimen for secondary CNS lymphoma. Co-authored publications on Zanubrutinib in relapsed/refractory marginal zone lymphoma (*Clinical Cancer Research*), and survival outcomes in plasmablastic lymphoma (*Blood*) have also been widely cited. She recently published national BCSH guidelines for marginal zone and mantle cell lymphomas as well as review articles in follicular lymphoma.



### Justin Loke

Dr Justin Loke trained at the University of Cambridge and Oxford Medical Schools and then completed postgraduate haematology training in Birmingham. His specialist interest is in myeloid haematological malignancies, including Acute Myeloid Leukaemia (AML). He completed a Kay Kendall Leukaemia Fund Clinical Research Fellowship at the University of Birmingham under the supervision of Professor Constanze Bonifer, investigating epigenetic dysregulation in AML by RUNX1 fusion proteins. Dr Loke subsequently completed a post-CCT fellowship (under Professor Charlie Craddock), with the CRUK Clinical Trials Unit, Birmingham, where he managed patients undergoing allogeneic stem transplantation and he was also involved in the development of supportive care studies in AML, including PACE and PROPEL. He remains secretary of the supportive care subgroup of the AML research network. He subsequently completed an AACR-CRUK Transatlantic Fellow based in the Dana-Farber Cancer Institute, Boston, USA with Professor Ben Ebert developing in vivo CRISPR system-based technologies to better understand haematopoiesis. He has recently been appointed at the CRUK Manchester Institute and as an honorary Consultant Haematologist at The Christie Hospital, Manchester, UK.



### **Paul Maciocia**

Paul Maciocia is a Clinician Scientist and Group Leader at the UCL Cancer Institute, specialising in T-cell cancers, allo-CAR-T therapies, and T cell engineering. He has led the development and clinical translation of multiple receptor-based therapies for T-cell lymphoma, T-ALL, and allo-CAR-T treatments for B cell malignancies. His work focuses on advancing novel immunotherapies to improve outcomes for patients with challenging haematological malignancies.



### **Charlotte Manisty**

Professor Charlotte Manisty is Head of Clinical Cardiovascular Research at University College London and is currently Clinical Director of Cardio-Oncology at Barts Heart Centre. She is Vice Chair of the Project Grants Committee for BHF and Secretary of the British Cardio-Oncology Society. She is on the Board of the International Society for Cardiovascular MRI, and is Principal Investigator on multiple clinical research studies in cardio-oncology and cardiovascular imaging.



### **Jessica Manson**

Dr Jessica Manson is a Consultant Rheumatologist at University College Hospital and an Honorary Associate Professor at University College London. She is a general rheumatologist with a special interest in acute rheumatology and hyperinflammation. Dr Manson leads the multi-speciality haemophagocytic lymphohistiocytosis (HLH) service at UCLH; helping to manage complex patients from around the UK. She also co-founded and co-chairs HiHASC, a group of doctors and scientists committed to improving outcome for patients with HLH and other forms of hyperinflammation. The UK HLH Network won the 2025 British Society for Rheumatology Best Practice and Patient Choice awards. She did her PhD at UCL on lupus nephritis and now co-leads a hyperinflammation translational research program.



### **Adam Mead**

Adam Mead, FMedSci, is Professor of Haematology at the University of Oxford. He is the Clinical Lead for Myeloproliferative Neoplasms (MPN) at Oxford University Hospitals NHS Foundation Trust and has served as Principal or Chief Investigator for over 60 clinical trials in MPN and chronic myeloid leukaemia (CML). From 2016 to 2022, he chaired the National Cancer Research Institute (NCRI) MPN Subgroup. Adam leads a research group at the MRC Weatherall Institute of Molecular Medicine, with a focus on discovering novel and rational therapeutic strategies to address the unmet clinical needs of people with MPN. His group's work, underpinned by cutting-edge single-cell genomics and experimental modelling, has revealed previously unrecognised heterogeneity among cancer stem cells in MPN. This includes the discovery of a key role for inflammation in driving therapy resistance and genetic evolution. In recognition of his contributions to the field, Professor Mead was elected a Fellow of the Academy of Medical Sciences in 2024.



### **Priyanka Mehta** **AML Registry Lead for Organising Committee**

Priyanka Mehta is a Consultant Haematologist at the University Hospitals Bristol and Weston NHS Trust, Bristol, UK. Dr Mehta's clinical and research interests are in the field of myeloid malignancies. Her academic interests include mechanisms of resistance and chemosensitivity of myeloid blasts in acute myeloid leukaemia (AML) and utilising comprehensive geriatric assessments for therapeutic decision making in older patients with myeloid malignancies. Her focus is also on the implementation of the best clinical and laboratory evidence in AML in the real world. As a member of the UK AML working party, she is leading the development of the first UK AML Registry.



### **Dragana Milojkovic**

Dragana Milojkovic is a Consultant Haematologist and Professor of Chronic Myeloid Malignancies at The Hammersmith Hospital, Imperial College London, UK, whose research and expertise focuses on chronic myeloid leukaemia, myeloproliferative neoplasms and transplantation. Professor Milojkovic is also Director of the Clinical Trials unit at The Hammersmith Hospital, has published extensively in peer reviewed journals regarding the biology and clinical management of CML, participates in CML ELN recommendations and BSH guidelines, is a member of EBMT Chronic malignancies working party and EICML, Chair of the UK CML sub-group ( 9/2019-9/2025) and member of the MPN UK sub-group.



### **Christopher Parrish**

Dr Parrish is Associate Professor of Haematology at Leeds Institute of Clinical Trials Research and Honorary Consultant Haematologist at St James's Institute of Oncology in Leeds, where he cares for patients with multiple myeloma and those undergoing stem cell transplantation. Chris has clinical and scientific interests in various aspects of myeloma care, including early and late phase clinical trials, immunotherapy, including immunodysfunction in myeloma, frailty and medical technology. Chris is the Clinical Trials Lead on the UKMRA Senior Leadership Team and is heavily involved with the national myeloma trial portfolio.



### **Piers Patten** **CLL Lead for Organising Committee**

Dr Piers Patten is a Clinical Senior Lecturer at King's College London and Consultant Haematologist at King's College Hospital and Guy's and St Thomas' Hospital. He chairs the UK CLL Trials Group and is an active investigator in multiple national and international clinical trials in CLL and lymphoma. His academic work spans both clinical and translational research, with over 50 peer reviewed publications and funding from the MRC, NIHR, Blood Cancer UK and the Leukemia and Lymphoma Society. He has co-authored national guidelines and contributes extensively to education and patient advocacy.



### **Charlotte Pawlyn**

Charlotte Pawlyn is a Clinician Scientist at The Institute of Cancer Research and a Haematology Consultant at The Royal Marsden Hospital NHS Foundation Trust. Charlotte leads the Myeloma Biology and Therapeutics Team at The Institute of Cancer Research which focusses on identifying therapeutic targets to improve outcomes for patients with immunomodulatory drug resistant and high-risk myeloma. In addition to her laboratory studies, Charlotte is actively involved in the Trial Management Groups of several clinical trials as part of the UK Myeloma Research Alliance including the large CRUK funded national frontline studies, Myeloma XI, Myeloma XIV (FITNEss) and Myeloma XVIII (iFIT) for which she is co-Cl.



### **Sue Pavord**

Sue Pavord is Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust, and President of the British Society for Haematology. She specialises in all aspects of medical haematology. She co-developed obstetric haematology as a subspecialty in the UK through education and research; was Director of the Leicester Comprehensive Care Haemophilia and Thrombosis Centre 2004-2014; led key changes to the management of immune thrombo-cytopenia during the COVID pandemic; steered the NHS response to vaccine-induced immune thrombocytopenia and thrombosis (VITT) and described the clinical features of this new condition. She has published over 200 papers in peer-reviewed journals, led and co-authored several national and international guidelines and produced two textbooks - the Obstetric Haematology Manual, and Iron in Clinical Practice. She is chief and principal investigator for pharmaceutical clinical trials.



**Beth Payne**  
**MDS Lead for Organising Committee**

Dr Payne is an Associate Clinical Professor of Haematology at UCL Cancer Institute and Honorary Consultant Haematologist at University College London Hospital. She trained in Clinical Medicine in Glasgow and Oxford, and completed haematology training in London. After completing her medical training, she undertook her PhD at the Dana-Farber Cancer Institute in Boston, USA. Her research and clinical practise is on disease understanding the sequential events leading to the development of myelodyslasia or acute myeloid leukaemia and develop novel therapeutics for early therapies for these conditions.



**Rakesh Popat**  
**Myeloma Lead for Organising Committee**

Dr Popat is a Consultant Haematologist at University College London Hospitals and Associate Professor at University College London with a specialist interest in multiple myeloma. He leads the myeloma clinical trials program and is the Cancer Program lead for the National Institute for Health Research (NIHR) University College London Hospitals Clinical Research Facility. Dr Popat completed his PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana-Farber Cancer Institute in Boston, MA, USA. Dr Popat is the Chair of the UK Myeloma Research Alliance (UKMRA), a member of the executive board of the UK Myeloma Society (UKMS) and the Young board of the European Myeloma Network (EMN). In addition, he is a member of the International Myeloma Working Group (IMWG) where he contributes to research and guidelines and the Principle Investigator for the NIHR Myeloma Health Informatics Collaborative. He is the Chief Investigator on many myeloma clinical trials and is particularly involved in the development of novel treatments, including T cell immunotherapies and new antibody approaches.



**Victoria Potter**  
**Cell Therapy and Transplant Lead for Organising Committee**

Dr Victoria Potter is a Consultant Haematologist with specialist interest in myeloid malignancies and stem cell transplantation at Kings College Hospital, London UK. She is the transplant and cell therapy programme director with specific interests in the development of clinical trials for AML and transplantation. She is a member of the AML UK Research Network where she co-chairs the relapse and trans-plantation sub-groups. Victoria has a number of national leadership roles including as current secretary of the BSBMTCT, deputy medical director for IMPACT (UK transplant trials network) and Chair of the Cell and Gene therapy sub-group of the National Haemoglobinopathy panel. Her research interests focus on the use of DLI for the prevention of relapse post-transplant and she is chief investigator/principal investigator for a number of clinical trials in AML, transplantation and cell therapy.



**Deepti Radia**

Deepti has been in her consultant post at Guy's and St Thomas' Hospitals since 2003. She is the lead clinician for the systemic mastocytosis and chronic myeloid leukaemia services. The ECRM UK mastocytosis centre of excellence at Guy's and St Thomas' Hospitals was jointly established by Deepti and Dr Clive Grattan in 2005. This nationally recognised service accepts referrals from across the UK, Ireland and further afield. Deepti is CI/PI for landmark trials for patients with advanced/symptomatic indolent systemic mastocytosis – PKC412, EXPLORER, PATHFINDER, APEX, PIONEER and HARBOR. She is a member of the study steering committee for the EXPLORER/PATHFINDER trials (Avapritinib in advanced SM) and APEX / SUMMIT trials (Bezuclastinib) for patients with advanced and symptomatic indolent SM. Deepti is actively involved in the education of clinicians and patients improve understanding of mast cell disorders by delivering regular teaching in regional, national, international meetings in addition to the UKMasto.org and TMS patient support groups.



### **Leo Rasche**

Prof Dr med Leo Rasche attended medical school at the University of Würzburg, Germany, where he received his MD degree in 2009 with a focus on experimental pathology, followed by a residency in internal medicine and a fellowship in internal medicine and hematology/oncology. From 2016 to 2018, he was a postdoctoral fellow at the Myeloma Institute at the University of Arkansas for Medical Sciences in Little Rock, where he studied medical imaging, tumor genomics, tumor evolution, and immunotherapy approaches for the treatment of multiple myeloma. In 2018, he was appointed Assistant Professor of Research at the University of Arkansas for Medical Sciences. In the summer of 2018, Dr Rasche returned to Germany, where he is an attending physician at the myeloma service of the University Hospital of Würzburg. In 2022, he completed his habilitation in internal medicine, and in 2024, he was appointed full professor of clinical and translational myeloma research at the University of Würzburg. Dr Rasche has published over 150 articles in peer-reviewed journals such as Nature Medicine, Nature Communications, Nature Reviews Clinical Oncology, Blood, and Leukemia. He presented his findings at national and international conferences, and serves as reviewer for prominent journals, including the New England Journal of Medicine. In 2022, he was awarded the Artur-Pappenheim Preis, one of the highest awards by the German Society of Hematology and Oncology. Dr Rasche holds membership with several professional organizations, including the International Myeloma Working Group (IMWG) and International Myeloma Society (IMS).



### **Claire Roddie**

Claire is a Consultant Haematologist at UCLH and Associate Professor in Haematology at UCL with a particular interest in adoptive cell therapies. She completed an Immunotherapy PhD at UCL with Karl Peggs and subsequently undertook a clinician scientist role with Martin Pule to develop the UCL CAR-T program. Claire's current role involves pre-clinical development of novel cell therapy projects, GMP manufacture and clinical trial design. She is also responsible for the advanced therapies clinical service at UCLH.



### **Sujith Samarasinghe**

Dr Sujith Samarasinghe completed his medical training at Imperial School of Medicine, London in 1998. He did his paediatric haematology training in Great Ormond Street Hospital (GOSH) and University College Hospital, London. He was awarded a PhD in 2010 from University College London in the field of immunotherapy for leukaemia. In 2011, he was appointed as a Consultant Haematologist in Newcastle but returned to GOSH in 2014. His areas of expertise include immuno-therapy in childhood leukaemia. He is a clinical trial coordinator for the national UK Acute lymphoblastic leukaemia trial, 2011 and for the European study ALLTogether 1. He has led on the ALLTogether 1 Down syndrome blinatumomab study and the UK blinatumomab study on chemotherapy replacement for patients who are chemotherapy intolerant and/or refractory. An update on both blinatumomab studies will be presented.



### **Sinisa Savic**

Sinisa is Professor of Clinical Immunology at the University of Leeds and Honorary Consultant Immunologist at St James's University Hospital. He trained in medicine at Newcastle University, later specialising in Clinical Immunology and completing a PhD at the Leeds Institute of Molecular Medicine. His clinical work is at the regional immunology service, providing specialist care for adults with immunodeficiencies, allergies, and systemic autoinflammatory syndromes. His research focuses on the molecular mechanisms driving genetically driven errors of immunity and immune-mediated inflammatory disorders, with recent work exploring the role of somatic mutations in acquired autoinflammatory syndromes, including VEXAS syndrome. He has set up and co-chairs national MDT for VEXAS syndrome. Professor Savic is also Chair of the British Society for Immunology's Clinical Immunology Professional Network and has served as principal or chief investigator on multiple clinical trials in hereditary angioedema and chronic urticaria and VEXAS.



**Emma Searle**  
**Early Trials and Trainee Engagement Lead for Organising Committee**

Dr Emma Searle is a Consultant Haematologist and deputy medical director of the NIHR Clinical Research Facility at The Christie Hospital, and an Honorary Senior Lecturer at the University of Manchester. Emma has a particular interest in early clinical drug development and translational research as and such is Chief Investigator and Principal Investigator of numerous clinical trials, including first in human trials. Prior to her current role, Emma completed a PhD in targeted cancer therapies then worked for the University of Manchester as a Clinical Lecturer alongside completion of her haematology training. Emma is Deputy Chair of the Experimental Cancer Medicine Centre Haematology Network Group, Chair of the British Society of Haematology Research and Grants Committee and a member of the UK AML Research Network and UK Myeloma Research Alliance.



**Frances Smith**

Frances is Head of Laboratory and Consultant Clinical Scientist, working for Synnovis in the Specialist Haematology Department at King's College Hospital, overseeing the provision of the molecular pathology and haemoglobinopathy genomics testing service. Frances is the operational laboratory lead for the 100,000 genomes project delivery at King's. Frances studied Genetics at the University of Sheffield, then worked at the Wellcome Trust Sanger Institute in the high throughput DNA sequencing laboratories. Frances moved to Guy's Genetics Laboratory to complete training as a Clinical Scientist in Molecular Genetics. Following registration, Frances moved to the Institute of Cancer Research to help set up a diagnostic laboratory specialising in next generation sequencing for patients with inherited cancer syndromes.



**Kate Stringaris**

Kate Stringaris is a Consultant Haematologist at University College London NHS Hospital. She earned her medical degree from UCL. She was appointed as a Senior Clinical Lecturer and Consultant Haematologist at St Bart's Hospital in London in 2014 after completing her PhD on the natural killer cell immune response to leukaemia at Imperial College London and her specialist haematology training at the Hammersmith and Royal Free Hospitals in London. She was a senior research clinician at the National Heart Lung and Blood Institute, National Institutes of Health in Bethesda, USA, between 2016 and 2021, where she worked on natural killer cell immunity, immune therapies for acute myeloid leukaemia and novel methods of stem cell transplantation. She is particularly interested in the treatment of acute myeloid leukaemia and the development of innovative therapies to improve patient outcomes through clinical practice, trials and research. She is a member of the national UK AML Research Network steering committee (previously NCRI) which meets regularly to design and refine new clinical trials in the field.



**Shaun Treweek**

Shaun is a trial methodologist interested in efficient trial design, particularly around inclusive recruitment and retention. He led the development of the NIHR INCLUDE Ethnicity Framework, a tool to help trialists design inclusive trials, PRO EDI, a tool to help systematic reviewers consider equity in their reviews, and PRECIS-2, a tool to match trial design decisions to what the users of the results need. He leads an initiative called Trial Forge ([www.trialforge.org](http://www.trialforge.org)) that aims to be more systematic about how we identify, generate and use research evidence in making trial design, conduct, analysis and reporting decisions.



### **Wai Keong Wong**

Wai Keong is a Consultant Haematologist in MPN and Diagnostics and a Clinical Director of Digital Transformation at Cambridge University Hospitals. He has held various digital leadership positions in Academic hospitals ranging from research to clinical operations and transformation.



### **Jurjen Versluis**

Dr Jurjen Versluis is a clinical hematologist at the department of Hematology at the Erasmus Medical Center Cancer Institute in Rotterdam, the Netherlands. He obtained his medical degree from the VU University, Amsterdam, the Netherlands, and PhD with distinction at the Erasmus University, Rotterdam. After completing his training in 2010, he joined the lab of Dr Coleman Lindsley at Dana-Farber Cancer Institute in Boston as a postdoc studying risk factors of AML/MDS treatment. Upon his return in 2021 to Rotterdam, he became the deputy director of the cell transplantation program. His main clinical and research interests are myeloid malignancies, acute leukemia, transplantation, and statistical innovation.



### **Maria Teresa Voso**

Maria Teresa Voso is a full Professor of Hematology at Tor Vergata University. She is director of the Laboratory of Advanced Diagnostics in oncohematology, and responsible for the MDS and APL programs at the same university. After a research fellowship at Beth Israel Hospital (Harvard Medical School) in Boston, US, she joined the Clinical Cooperation Unit between the Hematology Department of the University of Heidelberg and DKFZ, in Heidelberg, DE in 1996. In 1999, she moved to the Università Cattolica del Sacro Cuore in Rome Italy, and worked as Assistant Prof. of Hematology. Later, in 2014 she was appointed Associate Professor of Hematology at Tor Vergata University. Her work focuses the pathogenesis and the molecular diagnosis of AML, MPN and MDS, de novo and therapy related. She gained over 20 year experience in the treatment of MDS, AML and in particular APL, and has been national coordinator or PI of numerous trials in these diseases. Thanks to several national and international collaborations and continuative funding from National and International Agencies, she has published over 313 peer-reviewed articles and has an H-index of 51 (<https://orcid.org/0000-0002-6164-4761>).



### **Paresh Vyas** **Genomics and Translational Lead for Organising Committee**

Paresh Vyas is a clinical academic haematologist. He is Professor of Haematology at the University of Oxford and Deputy Director of the MRC Molecular Haematology Unit (MHU), Weatherall Institute of Molecular Medicine (WIMM) at the University of Oxford. He is clinical lead for AML (acute myeloid leukaemia) and high risk MDS (myelodysplasia) for the Oxford region and helps lead Phase I-III clinical trials in AML and MDS for the UK AML Trial Group. He formed the EVOLVE consortium, composed of HOVON, AMLSG and the UK AML Trial Group that now jointly plan pivotal Phase III AML/high risk MDS trials. He trained in Cambridge, Oxford and London. He did his PhD with Doug Higgs on globin gene regulation and his post-doctoral research with Dr Stuart Orkin at Children's Hospital Boston. His research focuses on the molecular and cellular biology of normal and leukaemic haemopoiesis, AML therapy, clonal haemopoiesis and allo-immune responses to leukaemia.

**Kwee Yong**

Kwee Yong is Professor of Haematology and Head of Research Department of Haematology at UCL. She is a Consultant Haematologist at UCLH, with a special interest in multiple myeloma. She leads national studies in multiple myeloma, ranging from national Phase 3 trials to first-in-human studies of novel therapies, including CAR-T cell studies. She runs a laboratory programme working on aspects of tumour biology and immunology in myeloma and precursor conditions. A particular research interest is smouldering myeloma and understanding the biological and immunological basis of progression to multiple myeloma.

**Robert Zeiser**

Robert Zeiser is Full Professor of Medicine and Director of the Division of Tumor Immunology at the Department of Hematology, Oncology, and Stem-Cell Transplantation at the Medical Center-University of Freiburg in Freiburg, Germany. In the last ten years Robert Zeiser has translated multiple therapeutic approaches from the mouse model into a clinical application in the fields of GVHD and leukemia immunotherapy. He translated the finding that ruxolitinib is highly effective against GVHD in mice (Blood 2014) into two new FDA approved therapies for patients with acute GVHD (NEJM 2020) or chronic GVHD (NEJM 2021) together with a team of other researchers. For his translational work Robert received the German Cancer Award 2021, which is the highest Award for Cancer Research in Germany and the Leibniz Award 2025, the highest research award over all science disciplines in Germany. Dr Zeiser received an ERC Advanced grant, the most prestigious and competitive funding scheme for researchers in Europe. He is Director of the Collaborative Research Center SFB 1479 that includes 17 research groups and investigates oncogene driven immune escape mechanisms. His lab is currently pursuing multiple projects that delineate the connection between oncogenic signalling and immune escape of leukemia.